FINWIRES · TerminalLIVE
FINWIRES

RBC Tweaks Estimates, Price Target for Repsol After Q1 Trading Update

-- RBC Capital Markets adjusted its earnings forecasts and price target for Repsol (REP.MC) amid a model update to reflect the Spanish energy group's first-quarter trading update and the research firm's revised commodity price deck.

"Repsol's trading update showed modest signs of downstream strength, with an average $10.9/bbl refining indicator, similar to 4Q, although this was clearly driven by a particularly strong March. Repsol notes refining margins in April have been volatile but have averaged ~$11.5/bbl (this is net of all variable costs, including transport), well below where we see prevailing margins. At a headline level, this could be seen as disappointing given where distillate cracks are on the screen; however, we think this reflects physical oil spreads, as well as timing effects between crude and product pricing. We've seen a number of 'messy' 1Q updates from the US refiners and XOM also over recent days, and Repsol as a coastal refiner may be more impacted by weaker capture than those in the US taking crude from local sources. We continue to see refining margins remaining structurally above mid-cycle levels through 2026 and into 2027, given tightness in distillate inventories, and see Repsol as a key beneficiary of this trend. In the upstream, production volumes were disappointing relative to our estimates, with some one-off impacts weighing on results," according to an April 10 note.

As such, the research firm revised its EPS estimates for full-year 2026 through 2028 and cut its first-quarter 2026 adjusted net income forecast to 985 million euros from 1.09 billion euros, 2% lower than market expectations.

Meanwhile, analysts lifted their price target for the outperform-rated stock to 32 euros from 29 euros. The upgrade accounts for the research firm's latest commodity price deck, which integrates higher 2026 to 2027 oil price forecasts and an $80 per barrel long-term Brent assumption.

相關文章

Asia

Dizal Pharma將在美國臨床腫瘤學會年會上發表三種藥物的研究成果。

根據週三在上海證券交易所發布的公告顯示,江蘇迪扎爾製藥(SHA:688192)表示,將在美國臨床腫瘤學會(ASCO)年會上公佈其新藥sunvozertinib片劑、golidocitinib膠囊和DZD6008的最新研究成果。 sunvozertinib和DZD6008皆用於治療非小細胞肺癌,而golidocitinib則用於治療T細胞淋巴瘤。研究結果顯示,這些藥物均取得了正面成果,尤其是DZD6008,其具有顯著的抗腫瘤活性且安全性良好。 該生技公司的股價在午盤交易中上漲不到2%。

$SHA:688192
Asia

Critica將於3月季度啟動西澳大利亞稀土計畫範圍界定研究。

根據週三提交給澳洲證券交易所的文件顯示,Critica(ASX:CRI)表示,位於西澳大利亞的Jupiter稀土計畫的初步研究已於今年3月季度正式啟動。 該研究整合了選礦、下游加工、基礎設施和開發假設,旨在確定一個基準開發路徑。 公司計劃在6月季度繼續完成Jupiter專案140個鑽孔的資源升級鑽探工作。此外,該公司還計劃準備並運送20,000公斤散裝樣品進行中試規模處理,以支援持續的最佳化、性能提升和中間精礦的生產。

$ASX:CRI
Asia

北太平洋銀行的收購要約確保了對卡里爾銀行的控制權

北太平洋銀行(東京證券交易所代號:8524)週三在東京證券交易所發佈公告稱,其對Career Bank的股份收購要約已獲成功,持股比例增至88.26%,使Career Bank成為其子公司。 北太平洋銀行此次收購了852,487股Career Bank股份,超過了完成交易所需的最低收購數量。 交易結算將於4月28日開始,屆時Career Bank將正式併入北太平洋銀行的財務報表。 北太平洋銀行計劃啟動相關程序,使Career Bank成為其全資子公司,並將其股票從札幌證券交易所下市。此次收購總成本約為15億日圓。

$TYO:8524